Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

Recruiting now · Phase 3

Conditions studied: Venous Thromboembolism (VTE), Postpartum

In brief

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.

Key facts

Study ID

NCT07140211

Run by

Marc Blondon

People needed

9200

Starts

2025-10-15

Expected to finish

2030-08-01

Last updated by the study team

2026-07-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

• ≥2 doses of postpartum LMWH
• Any indication for therapeutic anticoagulation
• A high-risk of postpartum VTE
• An increased bleeding risk
• A contra-indication to heparin

Where it is running

• Kantonsspital Baden — Baden, Switzerland (enrolling)
• Universitätsspital Basel — Basel, Switzerland (enrolling)
• Lindenhofspital — Bern, Switzerland (enrolling)
• Geneva University Hospitals — Geneva, Switzerland (enrolling)
• Centre Hospitalier Universitaire Vaudois — Lausanne, Switzerland (enrolling)
• Ente Ospedaliero Cantonale — Lugano, Switzerland (enrolling)
• Réseau Hospitalier Neuchâtelois — Neuchâtel, Switzerland (enrolling)
• Hôpital du Valais — Sion, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.